-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Lilly and Boehringer Ingelheim jointly announced that the SGLT2 inhibitor Jardiance (empagliflozin, empagliflozin) is in a phase 3 clinical trial for the treatment of patients with preserved ejection fraction heart failure (HFpEF) Reaching the primary endpoint significantly reduces the composite risk of cardiovascular death or hospitalization for heart failure in adult patients (with or without diabetes)
The press release states that this is the first SGLT2 inhibitor to significantly reduce the risk of cardiovascular death or heart failure hospitalization in this patient group
There are more than 60 million heart failure patients worldwide, and half of them suffer from HFpEF
Although patients with HFrEF have ushered in a variety of innovative therapies in recent years, there has been no FDA-approved therapy for HFpEF for many years, until Novartis' Entresto (sakubatril/valsartan, Chinese brand name Nuoxinto) was awarded in February this year.
Enpagliflozin is a highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor.
In June of this year, it was approved by the European Commission for the treatment of patients with HFrEF
The phase 3 clinical trial called EMPEROR-Preserved included 5988 HFpEF patients.
SGLT2 inhibitors were originally used as hypoglycemic therapy to treat patients with type 2 diabetes.
Note: The original text has been deleted
Reference materials:
[1] Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction.
[2] What's the Difference Between Systolic and Diastolic Heart Failure? Retrieved July 6, 2021, from https://